Novi antidepresivi

master's thesis

• Title (english): New antidepressants
• Author: Tin Matoš
• Mentor: Neven Henigsberg (mentor)
• Committee member: Ninoslav Mimica (predsjednik povjerenstva)
• Committee member: Dražen Begić (član povjerenstva)
• Committee member: Neven Henigsberg (član povjerenstva)
• Granter: University of Zagreb; School of Medicine; (Department of Psychiatry and Psychological Medicine); Zagreb
• Defense date and country: 2017-07-14, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Psychiatry
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Basic Medical Sciences; Pharmacology

Abstract

Globalna prevalencija depresivnih poremećaja je u porastu i predstavlja jedan od najistaknutijih zdravstvenih problema u današnjem svijetu. Još od 1950., kontinuirano se traga za što učinkovitijim antidepresivnim lijekovima. Od prve generacije tricikličkih antidepresiva (TCA) i inhibitora monoamino oksidaze (MAOI), kao i nove generacije inhibitora ponovne pohrane serotonina i noradrenalina (SSRI i SNRI), remisija se ostvaruje u prosječno dvije trećine bolesnika. Kako bi odgovorili na pitanje što učiniti s preostalom trećinom otpornom na terapiju i drugima koji imaju nezadovoljavajuće rezultate liječenja, u ovom radu će se nastojati naći rješenja u novim antidepresivima. Pregledavajući različite patofiziološke mehanizme nastanka i progresije depresivnih poremećaja, bit će uspoređeni različiti smjerovi razvoja antidepresiva. U fokusu će se naći antidepresivi atipičnog djelovanja, brzo djelujući NMDA antagonisti te lijekovi koji se vežu na višestruke receptore i oni pomoćni osnovnoj terapiji. Raspravljajući o farmakokinetici i komparativnoj učinkovitosti potencijalnih lijekova zaključit će se o njihovoj mogućnosti kontrole simptoma i trajanja depresivnih epizoda.

Abstract (english)

The global prevalence of depressive disorders is on a rise and it presents one of the most prominent health problems in the modern world. Since the 1950s there was ongoing work in the research for effective antidepressant medication. From the first generation tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), as well as the next generation selective serotonine and norepinephrine reuptake inhibitors (SSRIs and SNRIs), we get remission rates in about two thirds of the patients. To answer the question what should be done with the remaining third that is resistant to therapy and others with inadequate treatment regimen, this review proposes to look into novel pharmacotherapeutical approaches in treating depression. By reviewing different pathophysiological mechanisms of the onset and progress of depressive disorder, directions of antidepressant development will be compared. Focus will be at agents with atypicial mechanisms of action, rapid-acting agents like NMDA receptor antagonists and agents with multireceptor affinities, or those adjuvant to classic treatment. Discussing potential agents pharmacokintetic profile and comparative effectiveness conclusions will be drawn of their ability to control symptoms and duration of depressive episodes.

• Keywords: brzodjelujući antidepresivi; usporedba antidepresiva; novi pristup; neurotransmisija; mehanizam djelovanja; agomelatin; vortioksetin
• Keywords (english): rapid acting antidepressant; antidepressant comparison; novel approach; neurotransmission; mechanism of action; agomelatine; vortioxetine
• Language: croatian
• URN:NBN: urn:nbn:hr:105:879278
• Study programme: Title: Medicine; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2018-03-27 10:41:20